Sign in
Taking peoplePhase 3

Atropine in the Treatment of Myopia Study in Malaysia

Key facts

Who runs it
IDB VisionCare SDN BHD
Where
Malaysia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
144 people, planned
Started
17 Sept 2025
Expected to end
Sept 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Low dose atropine sulfate eye drops
  • Placebo
Record updated
9 January 2026

Who can take part

Age
5 years to 10 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Male or female children between 5 to 10 years of age
  • Children with refractive error of spherical equivalent -1.00 D up to -6.00 D in each eye
  • Children with active myopia progression of at least spherical equivalent -0.50 D within the last 12 months
  • Children with astigmatism of less than -1.50 D
  • Children having distance vision correctable to logMAR 0.2 or better in both eyes
  • A difference between non-cycloplegic subjective spherical refraction and cycloplegic subjective spherical refraction of not greater than -1.00 D
  • Children with normal intraocular pressure of not greater than 21 mmHg in either eye
  • Children with normal ocular health other than myopia
  • Children must be in good general health with no history of cardiac or respiratory diseases as per investigator's discretion and does not affect the study treatment or subsequent follow-ups
  • No asthma-requiring medications in the past one year
  • No known allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride
  • Willing and able to comply with scheduled visits and other study procedures
  • Written Informed Consent from parent and assent from child has been obtained

Who cannot take part

  • Children with prior and/or concomitant use of other myopia control drugs, contact lens or spectacles (except normal spectacles including tinted/anti-glare glasses) etc
  • Previous or current use of atropine or pirenzepine
  • Children participated in any clinical study within 30 days prior to randomization
  • History of hypersensitivity or allergy to study drug and/or any of the study medication ingredients
  • Children with ocular or systemic diseases which may affect vision or refractive error
  • Children with any ocular condition wherein topical atropine is contraindicated
  • Children with any other conditions precluding adherence to the protocol including unwillingness to refrain from the use of other myopia control drug, contact lens or spectacles (except normal) spectacles including tinted/anti-glare glasses) etc. for the duration of the study
  • Children with any other condition which may put the subject to risk during study or affect study results based on investigator's judgement
  • Children with congenital myopia
  • Children using Ortho K and Myopia Lens
  • Children with defective binocular function or stereopsis
  • Children with amblyopia (lazy eyes) or manifest strabismus including intermittent tropia

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 5 and 10 years old?

This trial is currently available in Malaysia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w/v Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.

The 2 groups in the trial

  • Atropine Sulphate 0.025% w/v Eye DropsExisting treatment, for comparison

    Participants will be instructed to administer one drop of Atropine Sulphate 0.025% w/v Eye Drops into each eye once daily at bedtime for a duration of 24 months.

    Treatment: Low dose atropine sulfate eye drops

  • PlaceboPlacebo, for comparison

    Participants will be instructed to administer one drop of Placebo Eye Drops into each eye once daily at bedtime for a duration of 12 months and Atropine Sulphate 0.025% w/v Eye Drops from 13-24 months onwards.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.
Criteria questions
Built from NCT07329777, who can take part
Record updated
9 January 2026